Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Review, H1 2016

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Review, H1 2016
Published Jun 15, 2016
69 pages — Published Jun 15, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Review, H1 2016, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted pipeline therapeutics.

The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics

Reasons to buy

  
Source:
Document ID
GMDHC0055TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Overview81
Therapeutics Development94
  Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Products under Development by Stage of Development91
  Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Products under Development by Therapy Area101
  Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Products under Development by Indication112
Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Pipeline Products Glance132
  Late Stage Products131
  Early Stage Products141
Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Products under Development by Companies153
Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Products under Development by Universities/Institutes182
Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Therapeutics Assessment207
  Assessment by Monotherapy/Combination Products201
  Assessment by Mechanism of Action212
  Assessment by Route of Administration232
  Assessment by Molecule Type252
Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Companies Involved in Therapeutics Development2711
  Alligator Bioscience AB271
  Apexigen, Inc.281
  Apogenix GmbH291
  Boehringer Ingelheim GmbH301
  Bristol-Myers Squibb Company311
  Celldex Therapeutics, Inc.321
  F. Hoffmann-La Roche Ltd.331
  Kyowa Hakko Kirin Co., Ltd.341
  Novartis AG351
  Seattle Genetics, Inc.361
  Zyrnat Biotherapeutics SL371
Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Drug Profiles3819
  2C-10 Drug Profile381
  ADC-1013 Drug Profile392
  APG-1233 Drug Profile411
  APX-005M Drug Profile422
  BI-655064 Drug Profile442
  bleselumab Drug Profile461
  BMS-986090 Drug Profile471
  CFZ-533 Drug Profile482
  FFP-104 Drug Profile501
  KGYY-15 Drug Profile511
  Monoclonal Antibodies to Agonize CD40 for Lymphoma Drug Profile521
  RG-7876 Drug Profile531
  SEA-CD40 Drug Profile541
  Vaccine to Target CD40 for Membranous Glomerulonephritis Drug Profile551
  ZY-11 Drug Profile561
Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Dormant Projects573
Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Discontinued Products601
Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Featured News &Press Releases617
  Apr 18, 2016: Seattle Genetics Highlights Data on SEA-CD40 at the American Association for Cancer Research Annual Meeting611
  Apr 13, 2016: Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences611
  Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn s Disease with anti-CD40 Monoclonal Antibody621
  Nov 17, 2015: Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune Checkpoint Inhibitors (ICI) Europe621
  Nov 06, 2015: Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting631
  Jun 16, 2015: Apexigen Doses First Patient in Phase 1 Clinical Trial of Its Immuno-oncology Therapeutic Antibody APX005M641
  May 28, 2015: Alligator Bioscience Phase 1 Trial Benefits from Cobra Biologics maxXpress Platform641
  Apr 27, 2015: First Patient Dosed by Alligator Bioscience in a Clinical Phase 1 Multicenter Trial651
  Apr 07, 2015: Alligator Bioscience Starts a Clinical Phase 1 Multicenter Trial651
  Feb 17, 2015: Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors661
  Dec 05, 2012: Boehringer Ingelheim And Apexigen Sign Manufacturing Agreement For Process Development And Early Stage Clinical Supply662
Appendix682
  Methodology681
  Coverage681
  Secondary Research681
  Primary Research681
  Expert Panel Validation681
  Contact Us681
  Disclaimer691

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tumor-Necrosis-Factor-Receptor-Superfamily-Member-5-B-Cell-Surface-Antigen-CD40-or-CD40L-Receptor-or-CD40-Pipeline-Review-H1-2016-2088-15961>
  
APA:
Global Markets Direct - Market Research. (2016). Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tumor-Necrosis-Factor-Receptor-Superfamily-Member-5-B-Cell-Surface-Antigen-CD40-or-CD40L-Receptor-or-CD40-Pipeline-Review-H1-2016-2088-15961>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.